TNG Transgene SA

Availability of Transgene’s Half-Year Financial Report as of June 30, 2025

Availability of Transgene’s Half-Year Financial Report as of June 30, 2025

TRANSGENE (Paris: TNG) today announced that it has made available to the public and filed with the Autorité des marchés financiers its half-year financial report as of June 30, 2025.

The document is available on the Company’s website: , in the “Investors/Financial information” section.

This report comprises the following documents:

  • 2025 half-year financial statements;
  • Half-year management report;
  • Statutory Auditors’ report on the 2025 half-year financial statements;
  • Declaration by the person responsible for this half-year financial report.

Contacts

Media: 



Caroline Tosch 

Corporate and Scientific Communications Manager 

+33 3 68 33 27 38 

  
 
Investors & Analysts: 
Nadège Bartoli 

Investor Relations Analyst and Financial Communication Officer

+33 3 88 27 91 03 
Lucie Larguier 

Chief Financial Officer

+33 3 88 27 91 00 

 

Attachment



EN
16/09/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Transgene SA

Jamila El Bougrini ... (+2)
  • Jamila El Bougrini
  • Thibaut Voglimacci-Stephanopoli
 PRESS RELEASE

Transgene and BioInvent to Present Translational Data and Updated Clin...

Transgene and BioInvent to Present Translational Data and Updated Clinical Results on Armed Oncolytic Virus BT-001, at ESMO 2025 Poster presentation on BT-001 in combination with pembrolizumab has shown tumor shrinkage in both injected and non-injected lesions Strasbourg, France, and Lund, Sweden, October 13, 2025, 8:30 a.m. CEST – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, and BioInvent International AB (“BioInvent”) (Nasdaq Stockholm: BINV), a biotech company focused on the discovery and developmen...

 PRESS RELEASE

Transgene et BioInvent présentent des données translationnelles et la...

Transgene et BioInvent présentent des données translationnelles et la mise à jour des résultats cliniques du virus oncolytique armé BT-001 à l’ESMO 2025 La présentation d’un poster de BT-001 en combinaison avec pembrolizumab montre une réduction tumorale dans des lésions injectées et non injectées Strasbourg, France, et Lund, Suède, le 13 octobre 2025, 8 h 30 – Transgene (Euronext Paris : TNG), société de biotechnologie qui conçoit et développe des immunothérapies contre le cancer reposant sur des vecteurs viraux, et BioInvent International AB (« BioInvent ») (Nasdaq Stockholm : BINV), s...

 PRESS RELEASE

Transgene to Present New Immunological Data from Phase I Trial of Indi...

Transgene to Present New Immunological Data from Phase I Trial of Individualized Therapeutic Cancer Vaccine, TG4050, at SITC 2025 Strasbourg, France, October 3, 2025, 5:45 p.m.  CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, will present a poster highlighting in-depth analysis of the neoantigen-specific T cell response from the randomized Phase I trial of its individualized therapeutic cancer vaccine, TG4050, at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC). SITC will tak...

 PRESS RELEASE

Transgene présente de nouvelles données d’immunologie de la Phase I de...

Transgene présente de nouvelles données d’immunologie de la Phase I de TG4050, son vaccin thérapeutique individualisé, au SITC 2025 Strasbourg, France, le 3 octobre 2025, 17 h 45 – Transgene (Euronext Paris : TNG), société de biotechnologie qui conçoit et développe des immunothérapies contre le cancer reposant sur des vecteurs viraux, présente un poster, à la 40e conférence annuelle de la Société pour l’immunothérapie du cancer (SITC) mettant en avant l’analyse approfondie de la réponse cellulaire T spécifique des néoantigènes issue de l’essai randomisé de Phase I de son vaccin thérapeutiqu...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch